abs106.txt	background		adding	modified	folfox6	(folinic	acid	fluorouracil	and	oxaliplatin)after	chemoradiotherapy	lengthening	the	chemoradiotherapy-to-surgery	intervalis	associated	with	an	increase	in	proportion	of	rectal	cancer	patients	apathological	complete	response	objective	purpose	this	study	was	to	analyze	disease-free	overallsurvival	design	a	nonrandomized	phase	ii	trial	settings	conducted	at	multiple	institutions	four	sequential	groups	stage	or	iii	wereincluded	intervention	all	received	50	gy	radiation	concurrentcontinuous	infusion	for	5	weeks	each	group	received0	2	4	6	cycles	after	chemoradiation	before	totalmesorectal	excision	were	recommended	receive	adjuvant	chemotherapyafter	surgery	total	8	main	outcome	measures	powered	detect	differences	inpathological	which	reported	previously	andoverall	survival	are	outcomes	current	results	259	211	had	follow-up	median	59months	(range	9-125	mo)	mean	number	chemotherapy	differedamong	(p	=	0	002)	because	one	third	groupassigned	no	preoperative	folfox	did	not	any	significantly	yptnm	pathological	004	<0	001	001)	secondaryanalysis	including	only	who	â‰¥1	cycle	still	showeddifferences	between	03)	limitations	randomized	show	differencesin	data	available	19%	conclusions	increases	compliance	systemic	anddisease-free	locally	advanced	neoadjuvant	consolidation	may	have	benefits	beyond	increasingpathological	rates	see	video	abstract	athttp	//links	lww	com/dcr/a739
